1-20 of 214 results for subject:Oseltamivir
Librarians' tools
- Search time
- 0.254 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Oseltamivir
- We searched for
- subject_t:Oseltamivir OR subject_t:Tamiflu OR subject_ses:507362
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health what pharmaceutical companies supplied the Government's stockpile of Tamiflu.
To ask the Secretary of State for Health what pharmaceutical companies supplied the Government's stockpile of Tamiflu.
Roche is the only supplier of the Government’s stockpile of Tamiflu. There are currently no other suppliers of Tamiflu.
(4) what proportion of those diagnosed with influenza A subtype H1N1 received Tamiflu in the last 40 months;
[119295]
Paul Flynn:
(4) what proportion of those diagnosed with influenza A subtype H1N1 received Tamiflu in the last 40 months;
[119295]
Paul Flynn:
In the swine flu pandemic there were two suppliers of H1N1 vaccine. 32 million doses were ordered from Baxter and 90 million were ordered from GSK in June 2009. With Baxter, we utilised a break clause in our contract and cancelled remaining orders on 28 February 2010.
As the Department did not have a break clause with GSK, in line with their agreements with other countries, we entered into more detailed negotiations with a view to reaching a settlement that would be in the interests of both parties This settlement, reached in April 2010, resulted in savings of around a third of the original
value of the total orders with GSK. It involved the Department taking total deliveries of 34,838,500 doses of Pandemrix, including vaccine received up to the point of the agreement, the purchase of approx 16 million doses of H5N1 "bird flu" vaccine and courses of the antiviral Relenza to replace stock used in the pandemic.
H1N1 vaccine is no longer manufactured and, beyond the orders placed during the swine flu, no further orders have been placed.
H1N1 vaccine is no longer used as it has reached the end of its licensed shelf life. Centrally held stock, amounting to approx 20 million doses was destroyed. Subsequently, in England, unused stock of pandemic specific vaccine held centrally was disposed of by incineration. The cost of incineration was estimated at £115,000. Local national health service bodies will have been responsible for the disposal of stock held locally and details of local disposal costs are not held centrally.
3.8 million doses of vaccine were donated to the World Health Organisation at the time of the swine flu pandemic.
In the 2009 H1N1 pandemic over 2.7 million assessments were completed through the National Pandemic Flu Service which resulted in the distribution of 1.1 million antiviral medicines to symptomatic patients who contacted the NPFS and satisfied the eligibility criteria for access to antiviral medicines in England. In subsequent winters, the National Pandemic Flu Service was not used and antiviral medicines were prescribed and dispensed in the community in the normal way. The following amount of antiviral medicines were prescribed and then dispensed in the community (data on antivirals used in hospitals is not collected).
| Time
period | Oseltamivir
Phosphate—Tamiflu | Zanamivir—Relenza |
| 2010-11 | 38,798 | 1,359 |
| 2011-12 | 2,477 | 77 |
| 2012-13
(Quarter
1) | 851 | 8 |
| Source: ePACT data (England only) |
The Department has released the “high level pricing information” on pandemic flu vaccine spend up to the end of the vaccine deliveries in April 2010. The sum of payments to GSK and Baxter for all H1N1 vaccine received up to the point that all deliveries ceased was £239 million.
The total amount spent on antivirals is still considered commercial in confidence. However, specific arrangements are in place with Roche to ensure that Tamiflu returned shortly before it reaches the end of its shelf life can be replaced at a reduced price. Discussions are also taking place with GSK on a suitable shelf life extension programme for Relenza.
(2) what procedures the NHS has in place to ensure the use of the oldest stock of Tamiflu first.
(2) what procedures the NHS has in place to ensure the use of the oldest stock of Tamiflu first.
To ask Her Majesty's Government why the name and address of anyone collecting Tamiflu on behalf of a person diagnosed by telephone as suffering from swine flu has been recorded; whether the data will kept; if so, by whom and for how long; who will be allowed to access them;...
To ask Her Majesty's Government why the name and address of anyone collecting Tamiflu on behalf of a person diagnosed by telephone as suffering from swine flu has been recorded; whether the data will kept; if so, by whom and for how long; who will be allowed to access them;...
SI 2009/2230. Together with an explanatory memorandum from the Department of Health. Coming into force 21 August 2009.
SI 2009/2230. Together with an explanatory memorandum from the Department of Health. Coming into force 21 August 2009.
The Minister will be relieved to know that I do not have as many questions as the noble Earl, but I welcome the opportunity to consider this matter in a period of relative calm. At present there is no media hysteria on this and, although about 500 people are affected...
The Minister will be relieved to know that I do not have as many questions as the noble Earl, but I welcome the opportunity to consider this matter in a period of relative calm. At present there is no media hysteria on this and, although about 500 people are affected...
The Minister has covered a great deal of ground in his reply, for which I am grateful, conscious as I am that I ranged rather widely in my questions to him. I found his answers reassuring and thank him for that. I congratulate the many scientists and officials involved in...
The Minister has covered a great deal of ground in his reply, for which I am grateful, conscious as I am that I ranged rather widely in my questions to him. I found his answers reassuring and thank him for that. I congratulate the many scientists and officials involved in...
That the Grand Committee do consider the Medicines for Human Use (Miscellaneous Amendments) Regulations 2009 (SI 2009/1164). Relevant Document: 16th Report from the Merits Committee.
That the Grand Committee do consider the Medicines for Human Use (Miscellaneous Amendments) Regulations 2009 (SI 2009/1164). Relevant Document: 16th Report from the Merits Committee.
I am grateful to the noble Earl for giving us the opportunity to appear before the Committee today to discuss these regulations. It is right that the special legislative amendments that we passed last month are subject to the scrutiny of the Committee. Equally, I am sure noble Lords will...
I am grateful to the noble Earl for giving us the opportunity to appear before the Committee today to discuss these regulations. It is right that the special legislative amendments that we passed last month are subject to the scrutiny of the Committee. Equally, I am sure noble Lords will...
In moving the Motion standing in my name on the Order Paper, I shall speak, with the leave of the Committee, to the other two Motions, which are also in my name. These Motions are intended not only as a vehicle by which to probe the content of three important...
In moving the Motion standing in my name on the Order Paper, I shall speak, with the leave of the Committee, to the other two Motions, which are also in my name. These Motions are intended not only as a vehicle by which to probe the content of three important...